Ankylosing spondylitis: How diagnostic and therapeutic delay have changed over the last six decades

Clinical and Experimental Rheumatology

Volumn 30, Issue 4, 2012, Pages 561-565

  Salvadorini, G ^a   Bandinelli, F ^a   Delle Sedie, A ^b   Riente, L ^b   Candelieri, A ^c,d   Generini, S ^a   Possemato, N ^b   Bombardieri, S ^b   Matucci Cerinic, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c University Hospital of Cosenza   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Ankylosing spondylitis; Anti TNF; Axial spondyloarthritis; Diagnostic delay; Sacroiliitis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DELAYED DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK SACROILIAC RADIOLOGICAL SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOTHERAPY; PRIORITY JOURNAL; SACROILIAC JOINT; SACROILIITIS; SCINTIGRAPHY; SCORING SYSTEM; THERAPY DELAY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; DELAYED DIAGNOSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RADIONUCLIDE IMAGING; RHEUMATOLOGY; SACROILIITIS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867356585     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. CARETTE S, GRAHAM D, LITTLE H, RUBENSTEIN J, ROSEN P: The natural disease course of Ankylosing spondylitis. Arthritis Rheum 1983; 26: 186-90.
2. BRAUN J, SIEPER J: Ankylosing spondylitis. Lancet 2007; 369: 1379-90.
3. RUDWALEIT M, KHAN MA, SIEPER J: The challenge of diagnosis and classification in early Ankylosing Spondylitis: do we need new criteria? Arthritis Rheum 2005; 52: 1000-8.
4. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
5. ZINK A, BRAUN J, LISTING J, WOLLENHAUPT J: Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - result from the German Rheumatological Database. J Rheumatol 2000; 27: 613-22.
6. CHORUS AM, BOONEN A, MIEDEMA HS, VAN DER LINDEN S: Employment perspectives of patients with ankylosing spondylitis. Ann Rheum Dis 2002; 61: 693-9.
7. BRAUN J, BARALIAKOS X, GOLDER W et al.: Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: valuation of a new scoring system. Arthritis Rheum 2003; 48: 1126-36.
8. RUDWALEIT M, BARALIAKOS X, LISTING J, BRANDT J, SIEPER J, BRAUN J: Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during therapy with the anti-TNF agent etanercept. Ann Rheum Dis 2005; 64: 1305-10.
9. RUDWALEIT M, LISTING J, BRANDT J, BRAUN J, SIEPER J: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-70.
10. SIEPER J, VAN DER HEIJDE D, LANDEWÉ R et al.: New criteria for inflammatory back pain in patients with chronic back pain - a real patient exercise by experts from the Assessment of Spondylo Arthritis international Society (ASAS). Ann Rheum Dis 2009; 68: 784-8.
11. AGGARWAL R, MALAVIYA A: Diagnosis delay in patients with ankylosing spondiylitis: factor and outcomes-an Indian perspective. Clin Rheumatol 2009; 28: 327-31.
12. FELDTKELLER E, ERLENDSSON J: Definition of disease duration in ankylosing spondylitis. Rheumatol Int 2008; 28: 693-6.
13. CALIN A, PORTA J, FRIES JF, SCHURMAN DJ: Clinical history as a screening test for ankylosing spondylitis. JAMA 1977; 237: 2613-4.
14. DINCER U, CAKAR U, DURSUN M: Diagnosis delay in patients with ankylosing spondylitis: possible reasons and proposals for new diagnostic criteria. Clin Rheumatol 2008; 27: 457-62.
15. GRAN JT, SKOMSVOLL JF: The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997; 36: 766-71.
16. BRAUN J, SIEPER J: Ankylosing spondylitis. Lancet 2007; 369: 1379-90.
17. COLLANTES E, ZARCO P, MUÑOZ E et al.: Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. Rheumatology (Oxford) 2007; 46: 1309-15.
18. MAU W, ZEIDLER H, MAU R et al.: Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow-up. J Rheumatol 1988; 15: 1109-14.
19. BRAUN J, BOLLOW M, EGGENS U, KONIG H, DISTLER A, SIEPER J: Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37: 1039-45.
20. CALIN A, ELSWOOD J, RIGG S et al.: Ankylosing spondylitis - an analytical review of 1500 patients: the changing pattern of disease. J Rheumatol 1988; 15: 1234-8.
21. HAIBEL H, SIEPER J: Use of methotrexate in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010; 28 (Suppl. 61): S128-31.
22. HELDMANN F, BRANDT J, VAN DER HORSTBRUINSMA IE et al.: The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011; 29: 672-80.
23. PALAZZI C, D'ANGELO S, CANTINI F et al.: Etanercept in spondyloarthropathies. Part I: Current evidence of efficacy. Clin Exp Rheumatol 2011; 29: 858-64.
24. REVICKI DA, LUO MP, WORDSWORTH P, WONG RL, CHEN N, DAVIS JC JR; ATLAS STUDY GROUP: Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 2008; 35: 1346-53.
25. BRAUN J, PHAM T, SIEPER J et al.: International. ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-24.